MedTrace Logo

A Study Comparing Imatinib and Imatinib/Pegylated Interferon in Chronic Myeloid Leukemia

NCT01227356 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 112

Last updated 2010-10-25

No results posted yet for this study

Summary

Patients with chronic myeloid leukemia in imatinib induced CHR are randomized between imatinib 400 mg daily and imatinib 400 mg daily + PegIntron 30 ug weekly.

Primary endpoint: To compare at 12 months between the treatment arms the rate of Major Molecular Response (=99,9% tumour reduction) at 12 months

Conditions

  • Health Care Quality
  • Health Care Evaluation

Interventions

DRUG

imatinib and pegylated interferon

imatinib 400 mg p.o. daily pegylated interferon 50 ug s.c. weekly

Sponsors & Collaborators

  • Uppsala University Hospital

    collaborator OTHER

  • Karolinska University Hospital

    collaborator OTHER

  • Uppsala University

    lead OTHER

Principal Investigators

  • bengt NO Simonsson, MD, PhD · Uppsala University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
95 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-09-30
Primary Completion
2009-03-31
Completion
2009-11-30

Countries

  • Sweden

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01227356 on ClinicalTrials.gov